This is a Clinical Study to Assess Whether the Combination of SJ733 and Tafenoquine Will be a Saf… (NCT07430592) | Clinical Trial Compass
Not Yet RecruitingPhase 2
This is a Clinical Study to Assess Whether the Combination of SJ733 and Tafenoquine Will be a Safe and Rapidly Acting Anti-malarial for the Radical Cure of P. Vivax Malaria
Peru104 participantsStarted 2026-07-01
Plain-language summary
The goal of this Phase 2b study is to examine the safety and efficacy of the combination of SJ733, an investigational agent, and tafenoquine for the radical cure of uncomplicated P. vivax malaria monoinfection in adult participants and determine the contributions of SJ733 to the effect. SJ733 will be administered in a 1-, 2-, or 3-day treatment schedule in combination with a single dose of tafenoquine.
Who can participate
Age range
18 Years – 76 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. is sterile prior to participating in the study.
. agrees to the use of a contraceptive method (such as a condom) through the administration of study treatment and for a period of 75 days after stopping study treatment.
. agrees to complete abstinence from intercourse throughout the study and for a period of 75 days after stopping study treatment.
Exclusion criteria
. AST/ALT \> 3 x upper limit of normal range (ULN) and total bilirubin is normal.
. AST/ALT \> 2 x ULN and total bilirubin is \>1 and \<2 x ULN and conjugated bilirubin is \> 2x ULN.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Parasitological Recurrence Free survival (RFS)
Timeframe: 14 - 180 days for each arm
2
Clinical Recurrence Free Survival
Timeframe: 14 to 180 days for each arm
3
Percentage of patients with treatment related adverse events
Timeframe: 1 to 180 days for each arm
4
Percent of patients with clinically significant abnormal vital signs
Timeframe: 1 to 180 days for each arm
5
Percent of patients with a decrease in hemoglobin (HB) > 2 g/dL from baseline to an absolute value of <7 g/dL
Timeframe: 1 to 180 days for each arm
6
Percent of patients with an Absolute Neutrophil Count < 1000/μL after baseline
Timeframe: 1 to 180 days for each arm
7
Percent of patients with significant changes in ECG findings